NAD Supplementation in Parkinson's Disease

This study is looking into whether Nicotinamide Riboside (NR), a form of Vitamin B3, can help people with Parkinson's disease. Researchers want to see if NR can improve blood vessel health in the brain, memory, and physical abilities. You might be able to join if you are 55 to 85 years old and have been diagnosed with Parkinson's disease (Hoehn and Yahr stages I-III). The study will compare participants who receive NR to those who receive a placebo (an inactive substance that looks like NR). Success would mean that NR improves measures of brain blood vessel health, memory test results, and physical function. The current recruitment status is unclear.

Study design: This is a randomized, placebo-controlled study with 40 participants. It compares Nicotinamide Riboside to a placebo.
What's involved: You would have 3 in-person visits over 12 weeks, including screening, a baseline visit, and a follow-up visit. Procedures include questionnaires, blood draws, memory and cognitive tests, brain activity measurements, walking and balance tests, grip strength, and wearing a study watch.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for 12 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NAD Supplementation in Parkinson's Disease

Enrolling by Invitation

NAAges 55–85InterventionalPrevention

University of Oklahoma

~40 participants

Updated 2026-08-12 on ClinicalTrials.gov

What's tested:Nicotinamide Riboside (NR)Oral placebo capsules

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in task-evoked neurovascular coupling response measured by functional near-infrared spectroscopy

Measured over Baseline to 12 weeks

Conditions

Parkinson's Disease

NCT07703137

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Center for Geroscience and Healthy Brain Aging
Oklahoma City, Oklahomano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Andriy Yabluchanskiy, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Oklahoma Health Campus

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Clinical diagnosis of Parkinson's disease according to Movement Disorder Society clinical diagnostic criteria (59), Hoehn and Yahr stages I-III at enrollment (ON medication state when applicable) (60).

Age ≥55 years at enrollment.

Adequate hearing and visual acuity to participate in the examinations

Ability to provide written informed consent in English.

Ability to complete study procedures, including seated tasks and walking tasks (with or without an assistive device, if needed for safety).

Stable antiparkinsonian medication regimen for ≥4 weeks prior to baseline (or drug-naive).

Exclusion

Not able to communicate or follow instructions due to aphasia or severe cognitive impairment.

Active CNS disease including multiple sclerosis, uncontrolled seizures, active cancer.

Cerebrovascular accident other than TIA within 60 days prior to Visit 0.

Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse.

Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0.

Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0.

Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.

Any other medical condition and/or unstable or severe medical illness which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol.

What this trial measures

Change in task-evoked neurovascular coupling response measured by functional near-infrared spectroscopyBaseline to 12 weeks
Neurovascular coupling will be assessed using functional near-infrared spectroscopy during study tasks. The primary reported value will be the change in task-evoked oxygenated hemoglobin response (change in oxygenated hemoglobin concentration in micromolar) from baseline to the 12-week follow-up visit. Changes will be compared between participants assigned to nicotinamide riboside and participants assigned to placebo.

Trialytics